AVALO THERAPEUTICS, INC. Accounts Receivable, Allowance for Credit Loss
AVALO THERAPEUTICS, INC. (AVTX) had Accounts Receivable, Allowance for Credit Loss of $0 as of 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2021-03-08
- 2020-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2019-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2018-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2017-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-08 |
| 2019-12-31 | $0.00 10-K · filed 2020-03-11 |
| 2018-12-31 | $0.00 10-K · filed 2019-03-18 |
| 2017-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |